INOVIO announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer commonly known as throat cancer. Under the terms of the supply agreement, Coherus will provide LOQTORZI (tor principalimab-tpzi), for a Phase 3 clinical trial to be conducted by INOVIO, pending alignment with the U.S. Food and Drug Administration (FDA) on study design. LOQTORZI is a PD-1 inhibitor recently approved by the FDA for the treatment of recurrent locally advanced/metastatic nasopharyngeal carcinoma (R/P NPC).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.04 USD | +5.70% | -1.45% | -38.74% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
10.57 USD | +4.40% | +9.19% | 274M | ||
2.04 USD | +5.70% | -1.45% | 232M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.74% | 232M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CHRS Stock
- News Coherus BioSciences, Inc.
- INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi)